Clinical Trials
Clinical Trials at Thangam Cancer Center
Advancing Tomorrow’s Treatments. Today.
At Thangam Cancer Center, we believe innovation is the heart of progress in cancer care. Our Clinical Trials program is a testament to this belief—pioneering cutting-edge therapies, targeted drugs, immunotherapies, and novel treatment combinations that could redefine the future of oncology. These trials are not just research—they’re hope in motion. Hope for better outcomes, fewer side effects, and longer, healthier lives.
All clinical trials at Thangam are conducted with the highest ethical standards, stringent protocols, and regulatory oversight. Participation is entirely voluntary and requires informed consent, ensuring patients and families are fully aware of the potential benefits and risks involved. Before enrollment, each patient undergoes a thorough medical screening to assess eligibility based on the specific criteria of each trial.
| TYPE | STUDY NAME | INDICATION | INVESTIGATIONAL STUDY | PHASE | STUDY STATUS & PATIENT REQUIREMENT | SPONSOR |
|---|---|---|---|---|---|---|
| Drug | AZ/BE/04/17/11 | Metastatic Cancer | Capecitabine | Phase III | Completed | AZIDUS PHARMACEUTICS |
| Drug | ARL/CT/18/004 | Colorectal Cancer | Trifluridine/Tipiracil | Phase III | Completed | ACCUTEST PHARMACEUTICS |
| Drug | 0063-17 | Triple Negative Breast Cancer | Nanosomal Docetaxel Lipid Suspension | Phase III | Completed | INTAS PHARMACEUTICS |
| Drug | 0586-18 | non-squamous non-small cell lung cancer | INTP24 | Phase III | Completed | INTAS PHARMACEUTICS |
| Drug | RITU.17.001 | Diffuse large B-cell Lymphoma | Rituximab | Phase III | Completed | CADILA HEALTH CARE |
| Drug | TDM1.17.001_ | Her2 Positive breast cancer | Trastuzumab emtansine | Phase III | Completed | CADILA HEALTH CARE |
| Vaccine | NCOV.20.002 | COVID Vaccination | Inj.Zycov | Phase III | Completed | ZYDUS & CADILA |
| Drug | IP Chemo Gastric | Gastric Cancer | NIPS | Phase III | Completed | THANGAM HOSPITAL |
| Drug | IP Chemo PMP | Pseudomyxoma Peritonei | NIPS | Phase III | Completed | THANGAM HOSPITAL |
| Drug | Proluton | Breast Cancer | Progesterone | Phase III | Completed | TATA HOSPITAL |
| Drug | BZ 02001 | Metastatic Cervix Cancer | Bevacizumab | Phase III | Completed | Ecron Acunova |
| Drug | 20160372 | Relapsed mutiple myleoma | Inj.Carfilzomib | Phase IV | Completed | IQVIA |
| Drug | D9106C0001 - Aegean | Non small cell lung cancer | Duruvalumab | Phase III | Completed | ASTRAZENECA |
| Drug | 0351-20 | Epithelial ovarian cancer study | Paclitaxel | Phase III | Completed | INTAS |
| Drug | BIO-PERTUZ | Breast Cancer | Pertuzumab | Phase III | Ongoing | BIOCON BIOLOGICS |
| Drug | ICS/CUR/2023-006 | Metastatic Colorectal Cancer | Bevacizumab + XELOX | Phase III | Ongoing | CURA TEQ |
| Drug | MONO-OLA1 | Endometrioid Ovarian Cancer | Tab.Olaparib | Phase III | Completed | ASTRAZENECA |
| Drug | Neo-ADAURA | Resectable NSCLC_EGFR Positive Lung Cancer | Tab.Osimertinib | Phase III | Completed | ASTRAZENECA |
| Drug | PACIFIC-8 | Unresectable Non-small Cell Lung Cancer | Durvalumab + Domvalanimab/Placebo | Phase III | Ongoing | ASTRAZENECA |
| Drug | Add-Aspirin | Breast Cohort ,GE Cohort,\nColorectal Cohort, Prostate Cohort\n | Tab.Aspirin /Placebo | Phase III | Ongoing | TATA HOSPITAL |
| Drug +Radiation | Neo-CHIMERA | Neoadjuvant Chemoimmunotherapy before chemoradiation vs. chemoradiation alone for Stage IIB-IIIC1 Carcinoma Cervix | Standard of Care ( Chemo Immunotherapy + Concurrent Chemo radaiation | Phase III | Ongoing | CMC Vellore |
| Drug | TROPION LUNG - 15 | EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer(Post Osimertinib Progression) | Datapotamab Deruxtecan & Osimertinib | Phase III | Ongoing | Astrazeneca |
| Drug | CRSF | Head and neck squamous cell carcinoma | Triple oral metronomic chemotherapy with low dose immunotherapy to standard intravenous chemotherapy (Cetuximab) | Phase III | Ongoing | Tata Memeorial |
| Drug | TMCI | Head and neck squamous cell carcinoma | Triple oral metronomic chemotherapy with low dose immunotherapy with low dose immunotherapy to standard intravenous chemotherapy (Nivolumab) | Phase III | Ongoing | Tata Memeorial |
| Drug | CTRT | locoregionally advanced unresectable esophageal and gastroesophageal junction cancer |
Carboplatin/paclitaxel versus cisplatin/5-fluorouracilas definitive chemoradiotherapy | Phase III | Ongoing | Tata Merioal Hospital |
| Drug | SUNRAY-02 | Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer | Olomorasib in Combination with Standard of Care Immunotherapy | Phase III | Site Selected | Eli Lilly |
| Supplimentory Mix | HUMOLYTE | Oral and Intestinal Mucositis in Patients with Cancer receiving Chemotherapy. | Humolyte Electrolyte mix with 2’-Fucosylactose | Phase III | Site Selected | IGH Naturals |
| Drug | NEO-X | Locally Advanced ResectableEsophageal Squamous Cell Carcinoma | Neoadjuvant Triple-Drug Chemotherapy Plus Low-Dose Immunotherapy Versus Neoadjuvant Chemoradiation | Phase III | Site Selected | Tata Memorial Hospital |
To join a Clinical trial
If you’re interested in being part of a trial that could not only help you but also pave the way for others, browse through the list of ongoing trials below. If eligible, fill out the form and our clinical research team will get in touch.